Home › Trials › NCT06855498

Continuation of treatment with povorcitinib for previous trial participants

A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

PHASE3 · Incyte Corporation · NCT06855498

This study lets people who have already benefited from the medication povorcitinib in a previous trial keep using it to see if it continues to help with their Hidradenitis Suppurativa.

Quick facts

PhasePHASE3
Study typeInterventional
Enrollment600 (estimated)
Ages18 Years and up
SexAll
SponsorIncyte Corporation (industry)
Drugs / interventionsadalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab, povorcitinib
Locations318 sites (Birmingham, Alabama and 317 other locations)
Trial IDNCT06855498 on ClinicalTrials.gov

What this trial studies

This study allows participants who have previously completed a clinical trial involving povorcitinib to continue receiving the treatment. It focuses on individuals who have shown clinical benefit from the drug during their prior participation. The study aims to assess the ongoing safety and efficacy of povorcitinib in managing Hidradenitis Suppurativa. Participants must meet specific eligibility criteria, including having completed the parent study without safety concerns.

Who should consider this trial

Good fit: Ideal candidates are individuals who have previously participated in Incyte-sponsored trials of povorcitinib and demonstrated clinical benefit.

Not a fit: Patients who experienced safety or efficacy issues during their previous treatment with povorcitinib will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide continued access to an effective treatment for patients with Hidradenitis Suppurativa.

How similar studies have performed: Previous studies involving povorcitinib have shown promising results, indicating a potential for continued success in this rollover study.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Ability to comprehend and willingness to sign a written ICF for the study.
* Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
* Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
* Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
* Willingness to avoid pregnancy or fathering children as defined in the protocol.
* Willingness and ability to comply with the study Protocol and procedures.

Exclusion Criteria:

* Had been permanently discontinued from study treatment during the parent study.
* Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
* Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:

  * Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
  * Live, attenuated vaccine.
* Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
* Women who are pregnant (or who are considering pregnancy) or breastfeeding.
* Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
* Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
* Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Where this trial is running

Birmingham, Alabama and 317 other locations

+268 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Hidradenitis Suppurativa, INCB054707, povorcitinib, Hidradenitis, HS

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.